TrovaGene Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

TROV 4.53 0.00 (0.00%)
price chart
Why Is Trovagene Inc. (TROV) Stock Soaring Today?
Shares of molecular diagnostics company Trovagene (TROV - Snapshot Report) are soaring today following news that the company has reached an agreement with America's Choice Provider Network (ACPN).
Stock Update (NASDAQ:TROV): TrovaGene Inc Announces Agreement with America ...  Smarter Analyst
Analysts Weigh In: Will Valeant Pharmaceuticals Intl Inc (VRX) and TrovaGene ...
Healthcare analysts from brokerage firms BMO and Cantor are out today with commentary on troubled drug makers Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and TrovaGene Inc (NASDAQ:TROV), as both companies appointed new CEOs today. Let's take ...
Time to Buy TrovaGene Inc (NASDAQ:TROV)
TrovaGene Inc (NASDAQ:TROV) has grabbed the attention from analysts, when it saw a value decrease of -8.25 percent in the last trading session.
Hot Stock to Track After Earnings: TrovaGene, Inc. (NASDAQ:TROV)
TrovaGene, Inc. (NASDAQ:TROV) reported earnings for the three months ended Mar2016 on May 10, 2016. The company earned $-0.35 per share on revenue of $0.12M.
TrovaGene, Inc. (NASDAQ:TROV) 1-Year High At $13.58  Equities Focus
Analysts Chime In on Three Volatile Biotech Stocks: TrovaGene Inc (TROV ...
Healthcare analysts are weighing in on molecular diagnostics firm TrovaGene Inc (NASDAQ:TROV), pharmaceutical company Keryx Biopharmaceuticals (NASDAQ:KERX), and mological drug maker OHR Pharmaceutical Inc (NASDAQ:OHRP), as the stocks ...
Why TrovaGene, Inc. (TROV) shares have been downgraded?
TrovaGene, Inc. (TROV) received a stock rating downgrade from Leerink Partners on April 26, 2016. In a note to investors, the firm issued a Mkt Perform rating.
Analyst Update: Catalyst Pharmaceuticals Inc, Newmont Mining Corp, and ...
Analysts are weighing in on drugmaker Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), commodity stock Newmont Mining Corp (NYSE:NEM), and molecular diagnostics specialist TrovaGene Inc (NASDAQ:TROV). Here's a quick roundup of today's brokerage ...
Trovagene, Inc. Announces Public Offering of Common Stock
SAN DIEGO, July 16, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering.
TrovaGene (TROV) Stock Tanks After Pricing Secondary Offering  TheStreet.com
Cantor Weighs In On Two Rising Biotech Stocks: TrovaGene Inc (TROV), Rosetta ...
It's a tale of two biotech firms this afternoon, as shares of TrovaGene Inc (NASDAQ:TROV) are up $0.73, or 20%, at $4.37, and shares of Rosetta Genomics Ltd.
TrovaGene, Inc. (TROV) Broker Price Targets For The Coming Week
02/03/2016 - TrovaGene, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 12 price target on the stock.
TrovaGene, Inc. (NASDAQ:TROV) PEG Ratio Is 0.0000  Vanguard Tribune